Meeting
2020 Genitourinary Cancers Symposium
Targeting resistant prostate cancer with ATR and PARP inhibition (TRAP trial): A phase II study.
Authors
Zachery R. Reichert
University of Michigan, Ann Arbor, MI
Zachery R. Reichert , Stephanie Daignault , Benjamin A. Teply , Michael Edward Devitt , Elisabeth I. Heath
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03787680
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS254)
Abstract #
TPS254
Poster Bd #
N20
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2022 ASCO Genitourinary Cancers Symposium
Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial).
First Author: Zachery R Reichert
Poster
2020 Genitourinary Cancers Symposium
Treatment response comparisons between ATM and BRCA2 germline carriers for mCRPC.
First Author: Alexandra Sokolova
First Author: Charles J. Ryan